Epigenetic biomarkers in lung cancer

Liloglou, Triantafillos; Bediaga, Naiara G.; Brown, Benjamin; Field, John K.; Davies, Michael

doi:10.1016/j.canlet.2012.04.018

Cited by 124 publications

(109 citation statements)

References 132 publications

Supporting

Mentioning

102

Contrasting

Unclassified

Order By: Relevance

“…Nonetheless, the fi ndings suggest even COPD in never smokers is still an important prognostic factor for NSCLC. In the present study, physiciandiagnosed COPD at admission was ascertained by self-report and may be associated with a certain degree modifi cation of NSCLC prognosis, 34 and studies have shown that COPD is associated with aberrant DNA methylation. 35 Additionally, COPD has been associated with several clinical comorbidities, 36 which may adversely affect the outcomes of coexisting NSCLC.…”

Section: Sensitivity Analysismentioning

confidence: 97%

The Impact of Coexisting COPD on Survival of Patients With Early-Stage Non-small Cell Lung Cancer Undergoing Surgical Resection

Zhai

Shafer

et al. 2014

Chest

117

114

View full text Add to dashboard Cite

Background: COPD is a recognized risk factor for lung cancer, but studies of coexisting COPD in relation to lung cancer outcomes are limited. We assessed the impact of COPD on overall survival (OS) and progression-free survival (PFS) in patients with early-stage non-small cell lung cancer (NSCLC). Abbreviations: HR 5 hazard ratio; HRadj 5 adjusted hazard ratio; MGH 5 Massachusetts General Hospital; NSCLC 5 non-small cell lung cancer; OS 5 overall survival; PFS 5 progression-free survival; SCC 5 squamous cell carcinoma

show abstract

Section: Sensitivity Analysismentioning

confidence: 97%

The Impact of Coexisting COPD on Survival of Patients With Early-Stage Non-small Cell Lung Cancer Undergoing Surgical Resection

Zhai

Shafer

et al. 2014

Chest

117

114

View full text Add to dashboard Cite

show abstract

“…In spite of the development in diagnostic and therapeutic methods, the outcome after treatment remains poor mainly because of the potential of tumor cells to invade and metastasize (Rasheed et al, 2010;Deng et al, 2014;Huang et al, 2014). Targeted therapies are commonly used in combination with traditional chemotherapy currently (Liloglou et al, 2014), and targeted drugs are more effective and have less severe side effects than standard chemotherapy drugs (Lammers et al, 2012). Under these circumstances, discovery of novel and effective biomarkers for lung cancer diagnosis and prognosis as well as new therapeutic targets becomes imperative.…”

Section: Introductionmentioning

confidence: 99%

Targeted Efficacy of Dihydroartemisinin for Translationally Controlled Protein Expression in a Lung Cancer Model

Liu

Wu²,

Guo³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Objective: Lung cancer is one of the malignant tumors with greatest morbidity and mortality around the world. The keys to targeted therapy are discovery of lung cancer biomarkers to facilitate improvement of survival and quality of life for the patients with lung cancer. Translationally controlled tumor protein (TCTP) is one of the most overexpressed proteins in human lung cancer cells by comparison to the normal cells, suggesting that it might be a good biomarker for lung cancer. Materials and Methods: In the present study, the targeted efficacy of dihydroartemisinin (DHA) on TCTP expression in the A549 lung cancer cell model was explored. Results and Conclusions: DHA could inhibit A549 lung cancer cell proliferation, and simultaneously up-regulate the expression of TCTP mRNA, but down-regulate its protein expression in A549 cells. In addition, it promoted TCTP protein secretion. Therefore, TCTP might be used as a potential biomarker and therapeutic target for non-small cell lung cancers.

show abstract

“…It is accepted that, the successful discovery, validation and implementation of specific molecular markers for early diagnosis and subsequent timely clinical intervention could vastly improve the appalling mortality rate for this devastating cancer [14].…”

Section: Discussionmentioning

confidence: 99%

Upregulated mrna expression of mtor in surgically resected early stage non-small cell lung carcinoma: a potential molecular targeted therapy

Sayan¹,

Çelik²,

Demiröz³

et al. 2017

Curr Thorac Surg

View full text Add to dashboard Cite

Epigenetic biomarkers in lung cancer

Cited by 124 publications

References 132 publications

The Impact of Coexisting COPD on Survival of Patients With Early-Stage Non-small Cell Lung Cancer Undergoing Surgical Resection

The Impact of Coexisting COPD on Survival of Patients With Early-Stage Non-small Cell Lung Cancer Undergoing Surgical Resection

Targeted Efficacy of Dihydroartemisinin for Translationally Controlled Protein Expression in a Lung Cancer Model

Upregulated mrna expression of mtor in surgically resected early stage non-small cell lung carcinoma: a potential molecular targeted therapy

Contact Info

Product

Resources

About